港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

醫藥外包概念

1,772.232

+40.7992.36%

漲家數：7

跌家數：- -

平家數：1

市盈率：- -

高：1,805.863

開：1,735.522

低：1,735.522

收：1,731.433

資料載入中...

總覽新聞資訊

石藥集團：I類新藥雙功能融合蛋白藥物JMT108獲臨牀試驗批准

漢邦科技過會：涉千萬元專利訴訟，IPO前藥明康德減持套現

神州細胞(688520.SH)控股子公司產品SCTT11獲得藥物臨牀試驗批准通知書

神州細胞：近日，公司控股子公司神州細胞工程有限公司收到國家藥監局核准簽發的《藥物臨牀試驗批准通知書》，同意公司自主研發的

恆瑞醫藥(600276.SH)子公司取得注射用SHR-A1811聯合方案的臨牀試驗批准

康龍化成03月06日主力淨流入323萬元散户資金拋售

藥明康德03月06日獲主力加倉119萬元

維亞生物03月06日獲主力加倉7萬元

盈警後傍上風口上的恆科指數，昭衍新藥(06127)為何一個半月股價漲近90%？

紅杉中國2025年的首個基石輪項目“雪王”，能破除基石虧損的“魔咒”嗎？

醫藥外包概念股集體走強維亞生物漲6.77% 機構指AI技術滲透加速CXO產業範式革新

藥明生物(02269)出現大手賣出24.55萬股，成交價$23.75，涉資583.062萬

阿斯达克财经

宜明昂科獲藥監局批准開展晚期惡性腫瘤臨牀試驗

“AI+”強勢迴歸，醫療ETF（512170）放量拉漲1.45%！CXO概念股集體衝高，巨頭藥明康德大漲3.5%

AI賦能製藥行業，推動藥物研發和臨牀試驗雙重突破

宜明昂科-B現漲超7% 獲批進行替達派西普聯合珀維拉芙普α的腫瘤臨牀試驗

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1576/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1576"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","market":"HK","secType":"PLATE","nameCN":"醫藥外包概念","latestPrice":1772.232,"timestamp":1741248510306,"preClose":1731.4331,"halted":0,"volume":100037287,"delay":0,"changeRate":0.023564,"change":40.79895,"pbRate":2.569388,"amount":2232823119,"amplitude":0.040626,"prevYearClose":1395.7731,"fiveDayClose":1794.354,"twentyDayClose":1587.977,"turnoverRate":0.00862,"marketCap":380565866496,"floatMarketCap":164754930944,"peRate":32.042796},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","high":1805.8632,"amplitude":0.040626,"preClose":1731.4331,"low":1735.5215,"pbRate":"2.569388","latestPrice":1772.232,"volume":100037287,"delay":0,"open":1735.5215,"prevYearClose":1395.7731,"prevWeekClose":1699.456,"prevMonthClose":1699.456,"prevQuarterClose":1395.773,"fiveDayClose":1794.354,"twentyDayClose":1587.977,"sixtyDayClose":1360.467,"secType":"PLATE","market":"HK","turnoverRate":0.00862,"peRate":32.042796,"marketCap":380565866496,"floatMarketCap":164754930944,"timestamp":1741248510306,"nameCN":"醫藥外包概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1576\",,,,undefined,":{"bkCode":"BK1576","up":7,"down":0,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1576\",pageSize:16,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517445159","title":"石藥集團：I類新藥雙功能融合蛋白藥物JMT108獲臨牀試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2517445159","media":"财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517445159?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 19:58","pubTimestamp":1741262311,"startTime":"0","endTime":"0","summary":"近日，石药集团发布JMT108获中国临床试验批准的公告。该产品是一种重组全人源抗PD-1且融合IL-15的双功能融合蛋白，通过靶向PD-1阳性肿瘤浸润免疫细胞，解除PD-1和PD-L1相互作用导致的免疫抑制，并通过PD-1抗体结合依赖性地激活IL-15下游信号通路，进一步促进相关免疫细胞的增殖和活化，从而达到增强的抗肿瘤疗效。本次获批的临床适应症为晚期恶性肿瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306200013abeb4e69&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306200013abeb4e69&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1521","LU0140636845.USD","LU1993786604.SGD","LU1226287529.USD","BK1576","03347","IE0008369823.USD","IE00B5MMRT66.SGD","01093","LU1226287792.SGD","LU1951186391.HKD","IE00BZ08YS42.EUR","LU1152091754.HKD","LU0880133367.SGD","LU1226288170.HKD","LU1226287875.USD","BK1515","IE00B031HY20.USD","LU0501845795.SGD","LU0072913022.USD","SG9999004220.SGD","LU1008478684.HKD","LU0326950275.SGD","LU1226288253.USD","IE00B543WZ88.USD","LU0067412154.USD","LU1960683339.HKD","BK1583","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","BK1141","LU1152091168.USD","LU1807302812.USD","BK1191","IE0008368742.USD"],"gpt_icon":0},{"id":"2517302511","title":"漢邦科技過會：涉千萬元專利訴訟，IPO前藥明康德減持套現","url":"https://stock-news.laohu8.com/highlight/detail?id=2517302511","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517302511?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 18:22","pubTimestamp":1741256543,"startTime":"0","endTime":"0","summary":"2月21日，江苏汉邦科技股份有限公司科创板IPO成功过会。2月24日，汉邦科技“光速”提交注册，公司距离“圆梦”资本市场又近一步。值得注意的是，汉邦科技曾获大客户药明康德增资入股，但药明康德却在公司IPO前夕减持。此外，应收账款逾期、存货库龄增长也是汉邦科技“头疼”的问题，而尚未解决的专利侵权案也给公司的IPO带来不确定性。不过，汉邦科技已申请该专利无效，正在等待审理中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/252399","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LU2125910500.SGD","LU2242644610.SGD","BK1141","02359","BK1576","LU2045819591.USD","BK1583","LU0320764599.SGD","LU0708995583.HKD","LU1046422090.SGD","LU0052750758.USD"],"gpt_icon":0},{"id":"2517213767","title":"神州細胞(688520.SH)控股子公司產品SCTT11獲得藥物臨牀試驗批准通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2517213767","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517213767?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 18:21","pubTimestamp":1741256482,"startTime":"0","endTime":"0","summary":"智通财经APP讯，神州细胞(688520.SH)发布公告，近日，公司控股子公司神州细胞工程有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，同意公司自主研发的产品SCTT11注射液开展甲状腺眼病适应症的临床试验。目前，临床上对于甲状腺眼病患者仍存在较大的未满足医疗需求，亟待研发新的治疗药物。SCTT11产品为公司以差异化竞争优势为目标自主研发的用于治疗甲状腺眼病的单克隆抗体注射液。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258655.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688520","BK1583","03347","BK0239","BK1576","BK1141"],"gpt_icon":0},{"id":"2517813731","title":"神州細胞：近日，公司控股子公司神州細胞工程有限公司收到國家藥監局核准簽發的《藥物臨牀試驗批准通知書》，同意公司自主研發的","url":"https://stock-news.laohu8.com/highlight/detail?id=2517813731","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517813731?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 18:19","pubTimestamp":1741256342,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0239","688520","BK1576","BK1141","03347","BK1583"],"gpt_icon":0},{"id":"2517013160","title":"恆瑞醫藥(600276.SH)子公司取得注射用SHR-A1811聯合方案的臨牀試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2517013160","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517013160?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 17:25","pubTimestamp":1741253103,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)公告，公司子公司苏州盛迪亚生物医药有限公司、上海盛迪医药有限公司收到国家药品监督管理局核准签发关于注射用SHR-A1811、贝伐珠单抗注射液、阿得贝利单抗注射液、SHR-8068注射液的《药物临床试验批准通知书》。临床试验具体为：注射用SHR-A1811联合方案治疗晚期实体肿瘤的开放、多中心Ib/Ⅱ期临床研究。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258595.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2148510915.USD","LU0405327148.USD","LU0405327494.USD","BK0060","BK0239","BK0188","BK0028","LU2328871848.SGD","LU1064131003.USD","03347","LU2488822045.USD","LU1328615791.USD","LU1969619763.USD","BK1141","BK0012","600276","LU1064130708.USD","BK1583","BK0196","BK0183","BK1576"],"gpt_icon":0},{"id":"2517513169","title":"康龍化成03月06日主力淨流入323萬元 散户資金拋售","url":"https://stock-news.laohu8.com/highlight/detail?id=2517513169","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517513169?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 16:17","pubTimestamp":1741249037,"startTime":"0","endTime":"0","summary":"03月06日, 康龙化成股价涨3.29%，报收16.32元，成交金额1.58亿元，换手率3.27%，振幅4.05%，量比1.02。康龙化成今日主力资金净流入323万元，上一交易日主力净流出182万元。该股近5个交易日下跌3.44%，主力资金累计净流出839万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流入5038万元，其中净流入天数为10日。该股主力净额占比0.07%，港股市场排名179/2651。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306170231abeb1535&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306170231abeb1535&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03759","BK1576","BK1141"],"gpt_icon":0},{"id":"2517313677","title":"藥明康德03月06日獲主力加倉119萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517313677","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517313677?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 16:16","pubTimestamp":1741248967,"startTime":"0","endTime":"0","summary":"03月06日, 药明康德股价涨4.23%，报收62.80元，成交金额4.00亿元，换手率1.66%，振幅3.07%，量比1.05。药明康德今日主力资金净流入119万元，连续4日净流入，上一交易日主力净流入2105万元。近一年数据显示，该股主力连续4日净流入后，次日上涨概率为72.73%，平均涨幅为2.67%。该股近5个交易日上涨0.40%，主力资金累计净流入1167万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入8570万元，其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306165601a262299f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306165601a262299f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02359","LU0320764599.SGD","LU2242644610.SGD","LU1046422090.SGD","BK1576","LU2045819591.USD","BK1141","LU2125910500.SGD","BK1583","LU0052750758.USD","LU0708995583.HKD"],"gpt_icon":0},{"id":"2517362421","title":"維亞生物03月06日獲主力加倉7萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517362421","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517362421?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 16:15","pubTimestamp":1741248905,"startTime":"0","endTime":"0","summary":"03月06日, 维亚生物股价涨7.52%，报收1.43元，成交金额999万元，换手率0.33%，振幅9.02%，量比1.41。维亚生物今日主力资金净流入7万元，上一交易日主力净流入3万元。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306165050a2622767&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306165050a2622767&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","BK1141","01873"],"gpt_icon":0},{"id":"2517182749","title":"盈警後傍上風口上的恆科指數，昭衍新藥(06127)為何一個半月股價漲近90%？","url":"https://stock-news.laohu8.com/highlight/detail?id=2517182749","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517182749?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 15:55","pubTimestamp":1741247703,"startTime":"0","endTime":"0","summary":"1月24日，昭衍新药披露盈警，预计2024年度归母净利润同比下降约77.8%到85.2%。此外，报告期内公司持有的生物资产市场价格下降，致使生物资产公允价值变动对业绩产生了消极影响。由此AH两地医药CXO和创新药强势大涨，提振整个医药情绪。而此轮行情的情绪溢价也出现在昭衍新药港股股价上。另外，今年以来，港股通资金一直在加大昭衍新药的持股比例，最高已达40.24%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258511.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06127","BK0216","BK1576","BK1141","603127"],"gpt_icon":1},{"id":"2517185579","title":"紅杉中國2025年的首個基石輪項目“雪王”，能破除基石虧損的“魔咒”嗎？","url":"https://stock-news.laohu8.com/highlight/detail?id=2517185579","media":"虎嗅","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517185579?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 14:25","pubTimestamp":1741242300,"startTime":"0","endTime":"0","summary":"红杉中国也是基石投资者之一，认购六千万美元。IT桔子数据显示，这不仅是红杉中国2025年的第一笔基石投资，还是其首次在消费赛道出手基石轮。此前红杉中国热衷投资医药项目基石轮，收益几何据IT桔子数据显示，头部VC机构红杉中国首次参与基石投资始于2020年，比知名PE机构高瓴投资要晚5年。2020年，红杉中国参与的基石轮投资项目有6家，是近几年来最多的；2021年-2023年，每年仅一两家，2024年红杉中国无公开基石投资。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306143723963bc34d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306143723963bc34d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1233","BK1576","HSTECH","HSCEI","06127","BK1141"],"gpt_icon":1},{"id":"2517512188","title":"醫藥外包概念股集體走強 維亞生物漲6.77% 機構指AI技術滲透加速CXO產業範式革新","url":"https://stock-news.laohu8.com/highlight/detail?id=2517512188","media":"金吾资讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517512188?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 13:48","pubTimestamp":1741240123,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药外包概念股集体走强，截至发稿，维亚生物 涨6.77%，康龙化成涨3.92%，泰格医药和药明康德涨3.24%，药明生物涨2.38%消息面上，国泰君安发布研报称，AI技术渗透加速CXO产业范式革新。AI技术在生物医药领域深度应用有望重构CXO产业价值链。全球药企降本增效诉求升级，叠加AI技术成熟度提升，驱动CXO企业加速智能化转型。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306134913963bb5f7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306134913963bb5f7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","BK1515","BK1161","03347","09939","BK1574","02359","01873","BK1141","03759"],"gpt_icon":0},{"id":"2517050659","title":"藥明生物(02269)出現大手賣出24.55萬股，成交價$23.75，涉資583.062萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2517050659","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517050659?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 11:00","pubTimestamp":1741230000,"startTime":"0","endTime":"0","summary":"[大手成交]药明生物(02269)在上午11:00出现大手卖出，成交量为24.55万，成交价为港币$23.75，涉资583.062万。至目前为止，股价升3.03%，今日最高价为$24.25，而最低价为$23.4，总成交量为2.77千万股，总成交金额港币$6.621亿。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145554547_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145554547_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2503068362/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU0181495838.USD","LU0516422366.SGD","LU0516422952.EUR","LU1688375341.USD","LU0051755006.USD","BK1610","LU0819121731.USD","LU0856984785.SGD","LU0572944931.SGD","IE00B0JY6N72.USD","LU2039709279.SGD","02269","LU0326950275.SGD","LU1880383366.USD","BK1576","BK1589","LU0320764599.SGD","LU0516422440.USD","BK1521","LU1242518857.USD","LU0043850808.USD","LU0140636845.USD","BK1141","SG9999002463.SGD","LU0588546209.SGD","LU0417516738.SGD","LU0823426480.USD","LU0348735423.USD","LU0359201612.USD","LU0307460666.USD","LU0823426308.USD","LU0348825331.USD","LU0359202008.SGD","LU0516423091.SGD","LU0417516902.SGD","LU1242518931.SGD","LU0979878070.USD","LU0327786744.USD","LU0456846285.SGD","LU1794554557.SGD","LU0039217434.USD","LU0708995583.HKD","LU1720050803.USD","SG9999002562.SGD","LU0516423174.USD","LU0456827905.SGD","LU0052750758.USD"],"gpt_icon":0},{"id":"2517547905","title":"宜明昂科獲藥監局批准開展晚期惡性腫瘤臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2517547905","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517547905?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 10:53","pubTimestamp":1741229580,"startTime":"0","endTime":"0","summary":"3月6日，宜明昂科-B发布公告，本公司已获得中华人民共和国国家药品监督管理局批准进行IMM01联合IMM2510，另加化疗或不加化疗用于治疗晚期恶性肿瘤的临床试验。这一进展标志着公司在推进IMM01及IMM2510的临床研究方面取得了重要里程碑。IMM01是公司核心产品，作为中国首个进入临床阶段的SIRPα-Fc融合蛋白，具有良好的安全性并已获得美国食品药品监督管理局授予的孤儿药资格。同时，IMM2510是公司自主研发的双特异性分子，旨在抑制肿瘤生成并增强免疫反应。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306105407989df88f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306105407989df88f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","BK1161","BK1583","01541","03347","BK1141"],"gpt_icon":0},{"id":"2517903108","title":"“AI+”強勢迴歸，醫療ETF（512170）放量拉漲1.45%！CXO概念股集體衝高，巨頭藥明康德大漲3.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517903108","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517903108?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 10:39","pubTimestamp":1741228740,"startTime":"0","endTime":"0","summary":"3月6日早盘，医疗板块全线反弹，CXO、AI医疗概念联袂领涨！博腾股份涨超5%，卫宁健康、药明康德涨超3.5%，康龙化成、昭衍新药、泰格医药等大幅跟涨。　　ETF方面，医疗ETF震荡走高，现涨1.45%，成交额突破3.6亿元。值得关注的是，昨日板块调整区间医疗ETF获大额资金逢跌增仓， 单日申赎净流入逾1.5亿元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2025-03-06/doc-inensrzm8043862.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0320764599.SGD","LU0052750758.USD","CXO","LU0456842615.SGD","LU1046422090.SGD","512170","LU2488822045.USD","159828","LU0708995583.HKD","BK1141","LU1997245177.USD","BK0216","02359","BK1583","LU2125910500.SGD","BK1576","LU2045819591.USD","603259","LU1997245094.SGD","LU2242644610.SGD"],"gpt_icon":0},{"id":"2517905640","title":"AI賦能製藥行業，推動藥物研發和臨牀試驗雙重突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2517905640","media":"财华社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517905640?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 10:37","pubTimestamp":1741228623,"startTime":"0","endTime":"0","summary":"随着人工智能技术的快速发展，AI制药行业正在迎来重要的技术突破与应用落地。AI技术，尤其是深度学习和数据分析的应用，正在重塑制药行业的研发模式，提升药物发现与开发的效率。从传统的药物研发流程来看，AI的介入使得药物筛选、临床试验设计、药物合成等环节变得更加高效且精准，显著降低了研发成本和时间。","market":"hk","thumbnail":"https://images.finet.hk/photoLib/title/202503_1/65534541-ee94-45a6-9ad3-850346f6c9f8.png","type":0,"news_type":0,"thumbnails":["https://images.finet.hk/photoLib/title/202503_1/65534541-ee94-45a6-9ad3-850346f6c9f8.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.finet.hk/newscenter/news_content/67c90a4f5a77124484e680e1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"finet_stock","symbols":["BK1141","BK1191","BK1583","BK1574","01477","BK1576","03347"],"gpt_icon":0},{"id":"2517903107","title":"宜明昂科-B現漲超7% 獲批進行替達派西普聯合珀維拉芙普α的腫瘤臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2517903107","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517903107?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 10:29","pubTimestamp":1741228140,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　宜明昂科-B（01541）早盘上涨7.18%，现报5.82港元，成交额2903.22万港元。\n　　3月6日，宜明昂科-B发布公告，集团已获中华人民共和国国家药品监督管理局（国家药监局）批准进行IMM01（替达派西普）联合IMM2510（珀维拉芙普α），另加化疗或不加化疗用于治疗晚期恶性肿瘤的临床试验。这一重大进展标志着公司在快速推进IMM01（替达派西普）及IMM2510（珀维拉芙普α）的临床研究方面又迈出了关键一步。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-03-06/doc-inensrzp6904547.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1576","01541","BK1583","03347","BK1161","BK1141"],"gpt_icon":0}],"pageSize":16,"totalPage":14,"pageCount":1,"totalSize":217}]}}